EA201492149A1 - St2-антигенсвязывающие белки - Google Patents
St2-антигенсвязывающие белкиInfo
- Publication number
- EA201492149A1 EA201492149A1 EA201492149A EA201492149A EA201492149A1 EA 201492149 A1 EA201492149 A1 EA 201492149A1 EA 201492149 A EA201492149 A EA 201492149A EA 201492149 A EA201492149 A EA 201492149A EA 201492149 A1 EA201492149 A1 EA 201492149A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- binding proteins
- methods
- antigen binding
- variants
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000055002 human IL1RL1 Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
В данном документе описаны составы и методы, относящиеся к антигенсвязывающим белкам, которые связываются с человеческим ST2, включая антитела. В конкретных вариантах осуществления изобретения предложены полностью человеческие антитела к ST2, а также их производные и варианты. Дополнительно предложены нуклеиновые кислоты, кодирующие такие антитела и фрагменты, варианты и производные антител. Также предложены способы получения и применения таких антител, включая способы лечения и предотвращения аутоиммунных и воспалительных заболеваний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649147P | 2012-05-18 | 2012-05-18 | |
US201361792619P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/041656 WO2013173761A2 (en) | 2012-05-18 | 2013-05-17 | St2 antigen binding proteins |
Publications (4)
Publication Number | Publication Date |
---|---|
EA201492149A1 true EA201492149A1 (ru) | 2015-03-31 |
EA201492149A8 EA201492149A8 (ru) | 2015-10-30 |
EA035160B1 EA035160B1 (ru) | 2020-05-08 |
EA035160B9 EA035160B9 (ru) | 2020-10-01 |
Family
ID=49584476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201492149A EA035160B9 (ru) | 2012-05-18 | 2013-05-17 | Антитела к st2 и их применение |
Country Status (37)
Country | Link |
---|---|
US (5) | US9382318B2 (ru) |
EP (2) | EP2850103B1 (ru) |
JP (5) | JP6205410B2 (ru) |
KR (5) | KR102161460B1 (ru) |
CN (3) | CN104334582B (ru) |
AP (1) | AP2014008053A0 (ru) |
AR (1) | AR091069A1 (ru) |
AU (2) | AU2013262593B2 (ru) |
BR (1) | BR112014028785B1 (ru) |
CA (2) | CA3182435A1 (ru) |
CL (1) | CL2014003131A1 (ru) |
CO (1) | CO7250445A2 (ru) |
CR (2) | CR20190225A (ru) |
DK (1) | DK2850103T3 (ru) |
EA (1) | EA035160B9 (ru) |
ES (1) | ES2818571T3 (ru) |
HK (1) | HK1208479A1 (ru) |
HR (1) | HRP20201341T1 (ru) |
HU (1) | HUE052442T2 (ru) |
IL (4) | IL282226B1 (ru) |
JO (1) | JO3623B1 (ru) |
LT (1) | LT2850103T (ru) |
MX (1) | MX356557B (ru) |
MY (1) | MY170099A (ru) |
NZ (1) | NZ700856A (ru) |
PE (2) | PE20150023A1 (ru) |
PH (1) | PH12014502527A1 (ru) |
PL (1) | PL2850103T3 (ru) |
PT (1) | PT2850103T (ru) |
RS (1) | RS60819B1 (ru) |
SG (1) | SG11201407564TA (ru) |
SI (1) | SI2850103T1 (ru) |
TN (1) | TN2014000434A1 (ru) |
TW (1) | TWI600664B (ru) |
UY (1) | UY34813A (ru) |
WO (1) | WO2013173761A2 (ru) |
ZA (1) | ZA201407937B (ru) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
WO2014152195A1 (en) | 2013-03-15 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
RU2019118984A (ru) | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
US10040859B2 (en) | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
CN104059130B (zh) * | 2014-06-27 | 2016-08-24 | 王方杰 | 关于st2蛋白抑制剂多肽及其应用 |
CN104017055B (zh) * | 2014-06-27 | 2016-09-14 | 鹿淑茹 | 一种关于st2蛋白抑制剂多肽及其应用 |
EP3218403B1 (en) | 2014-11-10 | 2020-05-13 | F.Hoffmann-La Roche Ag | Anti-interleukin-33 antibodies and uses thereof |
US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
WO2016122865A1 (en) | 2015-01-30 | 2016-08-04 | Salk Institute For Biological Studies | Compositions and methods for treating age-related diabetes and related disorders |
EP3733701A1 (en) | 2015-03-31 | 2020-11-04 | MedImmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
WO2017083242A1 (en) | 2015-11-13 | 2017-05-18 | The Regents Of The University Of Michigan | Inhibitors of suppression of tumorigencity 2 (st2) and methods using the same |
WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
BR112018014247A2 (pt) * | 2016-01-14 | 2018-12-18 | Anaptysbio Inc | inibição de reação alérgica usando um inibidor il-33 |
SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
CN107446040B (zh) * | 2016-05-30 | 2021-01-12 | 深圳市安群生物工程有限公司 | 人st2抗原表位肽、抗原、抗体、试剂盒及应用 |
CN107765014B (zh) * | 2016-08-23 | 2019-11-19 | 上海费玛生物科技有限公司 | 一种检测人sST2蛋白的方法以及试剂盒 |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
BR112019011799B1 (pt) | 2016-12-13 | 2021-12-21 | Delinia, Inc | Proteína de fusão, proteína dimérica e composição farmacêutica |
RU2771485C2 (ru) | 2017-02-10 | 2022-05-04 | Дженентек, Инк. | Антитела против триптазы, их композиции и применения |
EP3582802A4 (en) * | 2017-02-17 | 2021-02-17 | The General Hospital Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A BRAIN INJURY |
EP3957752A3 (en) | 2017-04-13 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
CA3088557C (en) | 2018-02-09 | 2024-02-27 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
IL307286A (en) * | 2018-04-11 | 2023-11-01 | Regeneron Pharma | Methods and preparations for quantification of IL-33 |
WO2020028784A1 (en) * | 2018-08-03 | 2020-02-06 | The Trustees Of Indiana University | Methods for targeting, inhibiting, and treating a tumor microenvironment |
JP2022513406A (ja) * | 2018-10-31 | 2022-02-07 | デリニア インコーポレイテッド | 多価制御性t細胞調節因子 |
US11739156B2 (en) * | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
CN110357963B (zh) * | 2019-07-31 | 2020-09-18 | 北京智仁美博生物科技有限公司 | 抗人st2抗体及其用途 |
CN114901361A (zh) | 2019-11-04 | 2022-08-12 | 免疫医疗有限公司 | 使用il-33拮抗剂的方法 |
WO2021089559A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
CN110921675A (zh) * | 2019-11-27 | 2020-03-27 | 成都理工大学 | 一种孔状CaB6纳米棒的制备方法 |
CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
CN111308086B (zh) * | 2020-02-21 | 2022-02-25 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性st2含量的酶联免疫检测试剂盒及用途 |
WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
AU2021253117A1 (en) | 2020-04-06 | 2022-12-01 | Medimmune Limited | Treating acute respiratory distress syndrome with IL-33 axis binding antagonists |
IL298075A (en) | 2020-05-12 | 2023-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | st2 antigen binding protein |
IL308597A (en) | 2021-06-11 | 2024-01-01 | Genentech Inc | A method for treating chronic obstructive pulmonary disease with an ST2 antagonist |
CN115920033A (zh) * | 2021-07-21 | 2023-04-07 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2抗体的制药用途 |
CN116284388A (zh) * | 2021-07-21 | 2023-06-23 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2的抗体以及包含其的液体组合物 |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
Family Cites Families (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
DE69131780T2 (de) | 1991-03-11 | 2000-11-16 | Univ Georgia Res Foundation At | Klonierung und expression der luziferase aus renilla |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
DE69332981T2 (de) | 1992-10-23 | 2004-05-19 | Immunex Corp., Seattle | Methoden zur herstellung löslicher, oligomerer proteine |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
JPH0731479A (ja) * | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスst2lをコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US5576191A (en) * | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US6455685B1 (en) | 1995-03-03 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
ATE290205T1 (de) | 1996-12-12 | 2005-03-15 | Prolume Ltd | Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen |
DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
US6326472B1 (en) | 1997-10-15 | 2001-12-04 | Schering Corporation | Human receptor proteins; related reagents and methods |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
GB9727172D0 (en) * | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
CA2324648C (en) | 1998-03-27 | 2013-02-26 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
US6566130B1 (en) | 2000-01-28 | 2003-05-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated gene expressed in prostate tissue |
WO2001070817A1 (fr) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
EP1334113A4 (en) | 2000-10-20 | 2007-08-08 | Expression Diagnostics Inc | EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL |
US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
JP2004519247A (ja) | 2001-03-20 | 2004-07-02 | オーソ・クリニカル・ダイアグノスティックス・インコーポレーテッド | 発現プロファイルおよび使用法 |
CA2447212A1 (en) | 2001-03-29 | 2002-10-24 | Incyte Genomics, Inc. | Secretory molecules |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
CA2457819A1 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
EP1446507A2 (en) | 2001-10-31 | 2004-08-18 | Pfizer Products Inc. | Therapeutics and diagnostics for disorders of erythropoiesis |
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US7507787B2 (en) | 2001-12-03 | 2009-03-24 | The University Of British Columbia | Effectors of innate immunity |
IL162300A0 (en) | 2001-12-03 | 2005-11-20 | Univ British Columbia | Effectors of innate immunity |
EP1534739A4 (en) | 2002-01-18 | 2006-05-31 | Bristol Myers Squibb Co | IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS THAT INTERACT WITH TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS |
JP2003235573A (ja) | 2002-02-13 | 2003-08-26 | Sumitomo Pharmaceut Co Ltd | 糖尿病性腎症マーカーおよびその利用 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CN1653080A (zh) | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | ***和血管的内皮细胞基因 |
US20030224422A1 (en) | 2002-04-08 | 2003-12-04 | St. Jude Children's Research Hospital, Inc. | Pre-and post therapy gene expression profiling to identify drug targets |
WO2003091391A2 (en) | 2002-04-23 | 2003-11-06 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
CN102533972B (zh) | 2002-05-09 | 2014-07-02 | 布赖汉姆妇女医院 | 作为心血管病的标志和治疗靶的1l1rl-1 |
JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
ATE499116T1 (de) | 2002-08-16 | 2011-03-15 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
RU2339647C2 (ru) * | 2002-08-19 | 2008-11-27 | Астразенека Аб | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
DK2213685T3 (en) * | 2002-09-06 | 2014-03-03 | Medarex Llc | Therapeutic anti-IL-1R1 monoclonal antibody |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
US20040106113A1 (en) | 2002-10-24 | 2004-06-03 | Mike West | Prediction of estrogen receptor status of breast tumors using binary prediction tree modeling |
AU2003290537A1 (en) | 2002-10-24 | 2004-05-13 | Duke University | Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
US20070015152A1 (en) | 2002-12-12 | 2007-01-18 | Novartis Ag | Methods for diagnosing and treating schizophrenia |
AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
ES2388280T3 (es) | 2002-12-20 | 2012-10-11 | Abbott Biotherapeutics Corp. | Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos |
JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
WO2004073657A2 (en) | 2003-02-19 | 2004-09-02 | Protein Design Labs, Inc. | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
US20070275374A1 (en) | 2003-03-17 | 2007-11-29 | Rinat Neuroscience Corp. | Methods For Idendifying Drug Targets And Modulators Of Neurons and Compositions Comprising The Same |
US7755007B2 (en) | 2003-04-17 | 2010-07-13 | K&H Manufacturing, Inc | Heated pet mat |
WO2004108899A2 (en) | 2003-06-04 | 2004-12-16 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Pni microarray and uses |
EP1631682A1 (en) | 2003-06-04 | 2006-03-08 | Agency for Science, Technology and Research | Differentially regulated hepatocellular carcinoma genes and uses thereof |
EP1641940A4 (en) | 2003-07-01 | 2009-09-02 | Mor Research Applic Ltd | DETERMINATION OF PROGNOSIS IN PATIENTS WITH EWING SARCOMA USING GENETIC PROFILING |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
JP2005204549A (ja) | 2004-01-21 | 2005-08-04 | Hubit Genomix Inc | C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用 |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス, インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
WO2005097421A2 (en) | 2004-04-01 | 2005-10-20 | Sequenom, Inc. | Methods for identifying risk of osteoarthritis and treatments thereof |
WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
CA2615122A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
AU2006280146B2 (en) | 2005-08-09 | 2012-06-28 | Immunogen, Inc. | Method of acylating maytansinol with chiral amino acids |
CN101395920A (zh) | 2006-03-01 | 2009-03-25 | 汤姆森特许公司 | 生成媒体包的设备与方法 |
CA2650201C (en) | 2006-04-24 | 2020-10-20 | James V. Snider | Predicting mortality and detecting severe disease |
US8865645B2 (en) | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
US7560530B1 (en) * | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
US8771700B2 (en) | 2006-08-23 | 2014-07-08 | Rutgers, The State University Of New Jersey | Interferon antagonists, antibodies thereto and associated methods of use |
US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
WO2008144610A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
PE20140614A1 (es) | 2007-07-16 | 2014-05-28 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
AU2009231733B2 (en) | 2008-03-31 | 2015-12-24 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
KR20230003298A (ko) | 2008-04-30 | 2023-01-05 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
US7879978B2 (en) * | 2009-03-31 | 2011-02-01 | Centocor Ortho Biotech, Inc. | Macaca fascicularis ST2L |
WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
SI2556090T1 (sl) | 2010-04-09 | 2016-07-29 | Critical Care Diagnostics, Inc. | Protitelesa in testi topnega človeškega ST-2 |
BR112013013460A8 (pt) | 2010-12-16 | 2019-02-12 | Genentech Inc | métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total |
WO2012113813A1 (en) * | 2011-02-23 | 2012-08-30 | F. Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2013
- 2013-05-16 AR ARP130101701A patent/AR091069A1/es unknown
- 2013-05-16 JO JOP/2013/0151A patent/JO3623B1/ar active
- 2013-05-16 UY UY0001034813A patent/UY34813A/es not_active Application Discontinuation
- 2013-05-17 MX MX2014013894A patent/MX356557B/es active IP Right Grant
- 2013-05-17 WO PCT/US2013/041656 patent/WO2013173761A2/en active Application Filing
- 2013-05-17 CA CA3182435A patent/CA3182435A1/en active Pending
- 2013-05-17 CA CA2873549A patent/CA2873549C/en active Active
- 2013-05-17 EP EP13790269.8A patent/EP2850103B1/en active Active
- 2013-05-17 IL IL282226A patent/IL282226B1/en unknown
- 2013-05-17 US US13/897,096 patent/US9382318B2/en active Active
- 2013-05-17 PE PE2014002021A patent/PE20150023A1/es active IP Right Grant
- 2013-05-17 NZ NZ700856A patent/NZ700856A/en unknown
- 2013-05-17 KR KR1020147031821A patent/KR102161460B1/ko active IP Right Grant
- 2013-05-17 AP AP2014008053A patent/AP2014008053A0/xx unknown
- 2013-05-17 CN CN201380025392.0A patent/CN104334582B/zh active Active
- 2013-05-17 PL PL13790269T patent/PL2850103T3/pl unknown
- 2013-05-17 JP JP2015512897A patent/JP6205410B2/ja active Active
- 2013-05-17 DK DK13790269.8T patent/DK2850103T3/da active
- 2013-05-17 KR KR1020207027543A patent/KR20200115662A/ko not_active IP Right Cessation
- 2013-05-17 PE PE2019001319A patent/PE20191408A1/es unknown
- 2013-05-17 KR KR1020237009097A patent/KR20230043229A/ko not_active Application Discontinuation
- 2013-05-17 CN CN201811129784.2A patent/CN109206517B/zh active Active
- 2013-05-17 CR CR20190225A patent/CR20190225A/es unknown
- 2013-05-17 LT LTEP13790269.8T patent/LT2850103T/lt unknown
- 2013-05-17 EP EP20160953.4A patent/EP3693395A1/en active Pending
- 2013-05-17 AU AU2013262593A patent/AU2013262593B2/en active Active
- 2013-05-17 PT PT137902698T patent/PT2850103T/pt unknown
- 2013-05-17 IL IL308770A patent/IL308770A/en unknown
- 2013-05-17 MY MYPI2014003183A patent/MY170099A/en unknown
- 2013-05-17 SI SI201331800T patent/SI2850103T1/sl unknown
- 2013-05-17 KR KR1020237041864A patent/KR20230170805A/ko not_active Application Discontinuation
- 2013-05-17 HU HUE13790269A patent/HUE052442T2/hu unknown
- 2013-05-17 RS RS20201118A patent/RS60819B1/sr unknown
- 2013-05-17 CN CN202211424290.3A patent/CN116333114A/zh active Pending
- 2013-05-17 ES ES13790269T patent/ES2818571T3/es active Active
- 2013-05-17 KR KR1020227025149A patent/KR20220107316A/ko not_active Application Discontinuation
- 2013-05-17 BR BR112014028785-6A patent/BR112014028785B1/pt active IP Right Grant
- 2013-05-17 SG SG11201407564TA patent/SG11201407564TA/en unknown
- 2013-05-17 EA EA201492149A patent/EA035160B9/ru unknown
- 2013-05-17 TW TW102117604A patent/TWI600664B/zh active
-
2014
- 2014-10-17 TN TN2014000434A patent/TN2014000434A1/fr unknown
- 2014-10-23 IL IL235308A patent/IL235308A0/en unknown
- 2014-10-30 ZA ZA2014/07937A patent/ZA201407937B/en unknown
- 2014-11-12 PH PH12014502527A patent/PH12014502527A1/en unknown
- 2014-11-18 CL CL2014003131A patent/CL2014003131A1/es unknown
- 2014-12-02 CO CO14265389A patent/CO7250445A2/es unknown
- 2014-12-17 CR CR20140585A patent/CR20140585A/es unknown
-
2015
- 2015-09-21 HK HK15109251.8A patent/HK1208479A1/xx unknown
-
2016
- 2016-06-10 US US15/178,652 patent/US9982054B2/en active Active
- 2016-07-07 JP JP2016134763A patent/JP6382260B2/ja active Active
-
2017
- 2017-05-22 US US15/601,868 patent/US10227414B2/en active Active
-
2018
- 2018-03-23 AU AU2018202097A patent/AU2018202097A1/en not_active Abandoned
- 2018-08-01 JP JP2018145066A patent/JP2019004885A/ja not_active Withdrawn
-
2019
- 2019-01-08 US US16/242,278 patent/US11059895B2/en active Active
- 2019-06-24 IL IL267599A patent/IL267599B/en active IP Right Grant
-
2020
- 2020-07-03 JP JP2020115457A patent/JP2020171305A/ja not_active Withdrawn
- 2020-08-26 HR HRP20201341TT patent/HRP20201341T1/hr unknown
-
2021
- 2021-06-04 US US17/339,301 patent/US11965029B2/en active Active
-
2022
- 2022-04-15 JP JP2022067550A patent/JP2022106790A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
EA201790330A1 (ru) | Белки, связывающиеся с bcma (cd269/tnfrsf17) | |
GB201112429D0 (en) | Antigen-binding proteins with increased FcRn binding | |
EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
EA201492101A1 (ru) | Антитела против fcrn | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
PH12013502205A1 (en) | Antibodies to il-6 and their uses | |
EA201290589A1 (ru) | Cd127-связывающие белки | |
EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
EA201890928A1 (ru) | Антигенсвязывающие белки, которые активируют лептиновый рецептор | |
EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
EA201171237A1 (ru) | Антитела к dkk-1 | |
EA201690503A1 (ru) | Антитела | |
EA201592285A1 (ru) | Антигенсвязывающие белки к рецептору онкостатина м | |
EA201590918A1 (ru) | Антитела к bmp-6 | |
CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent |